Lynparza Poised To Bring Targeted Therapy To Prostate Cancer

The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.

Prostate-cancer
Detailed data on Lynparza in prostate cancer was presented at ESMO • Source: Shutterstock

Detailed Phase III results of AstraZeneca PLC and Merck & Co. Inc.'s PARP inhibitor Lynparza (olaparib) impressed at the European Society for Medical Oncology meeting on 30 September. The results showed Lynparza doubled the time to radiographic progression-free survival (rPFS) in men with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed on hormone therapy.

They also showed an improvement in a broader population of men with homologous recombination repair (HRRm) gene mutations, though the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category